Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer

Timothy L. Ratliff; Eric O. Haaff; William J. Catalona

doi:10.1016/0090-1229(86)90043-7

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer

Timothy L. Ratliff^*, Eric O. Haaff, William J. Catalona

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

Original language	English (US)
Pages (from-to)	375-379
Number of pages	5
Journal	Clinical Immunology and Immunopathology
Volume	40
Issue number	2
DOIs	https://doi.org/10.1016/0090-1229(86)90043-7
State	Published - Aug 1986

ASJC Scopus subject areas

Immunology and Allergy
Pathology and Forensic Medicine
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0090-1229(86)90043-7

Cite this

@article{2d9b84a3ce014143b10ee6e265724f08,

title = "Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer",

abstract = "Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.",

author = "Ratliff, {Timothy L.} and Haaff, {Eric O.} and Catalona, {William J.}",

year = "1986",

month = aug,

doi = "10.1016/0090-1229(86)90043-7",

language = "English (US)",

volume = "40",

pages = "375--379",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer

AU - Ratliff, Timothy L.

AU - Haaff, Eric O.

AU - Catalona, William J.

PY - 1986/8

Y1 - 1986/8

N2 - Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

AB - Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=0022446011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022446011&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(86)90043-7

DO - 10.1016/0090-1229(86)90043-7

M3 - Article

C2 - 3487405

AN - SCOPUS:0022446011

SN - 1521-6616

VL - 40

SP - 375

EP - 379

JO - Clinical Immunology

JF - Clinical Immunology

IS - 2

ER -

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this